ClinicalTrials.Veeva

Menu

Red Wine Effects Upon Gut Flora and Plasma Levels of Trimethylamine-N-oxide (TMAO) - WineFlora Study

U

University of Sao Paulo General Hospital

Status

Completed

Conditions

Gut Microbiota
Trimethylamine-N-oxide
Effects of Red Wine
Atherosclerosis

Treatments

Dietary Supplement: Red Wine consumption
Other: Period without alcohol consumption

Study type

Interventional

Funder types

Other

Identifiers

NCT03232099
57379216.0.0000.0068
2015/212606 (Other Grant/Funding Number)

Details and patient eligibility

About

Recent evidence indicates that Trimethylamine-N-oxide (TMAO) is a pro-atherosclerotic, phosphatidylcholine-dependent metabolite of diet and intestinal flora. Food substrates derive from carnitine and phosphatidylcholine (lecithin), present mainly in eggs, red meat, liver and pork. The intestinal flora pattern that favors the formation of TMAO is very similar to that which predisposes to insulin resistance and obesity: a high proportion between phylum Firmicutes over Bacteroidetes. The intestinal microbiota is sensitive and variable; the use of prebiotics and probiotics can change the relationship between Firmicutes/Bacteroidetes phyla. Red wine (RW), for its composition with polyphenols and possible bactericidal role, may play a role in the intestinal flora modification and could promote proliferation of beneficial bacteria. However, the influence of RW on TMAO is not known. This is the hypothesis to be tested in this trial. METHODS: This is a prospective, crossover, randomized, controlled trial with patients from Heart Institute (InCor), FMUSP and volunteers recruited through press releases. We will evaluate 42 patients, all men, with established atherosclerotic disease. Patients will be evaluated in a crossed manner: each subject receives both treatments, intervention and control (in random order), and they will be divided into 2 groups: A and B. In the first intervention stage, after 2 weeks of washout for all patients , group A receives Red Wine (RW) and group B is the control, abstemious. In the 2nd stage of intervention, after 2 weeks of washout for all patients the groups are inverted: group B receives RW; and group A will be abstemious. In the period with wine intervention, patients will receive 250 mL/day of red wine per day, for 5 days of the week, for 3 weeks. Patients will maintain their usual diet without the use of prebiotics or probiotics, or other polyphenolic derivatives. At the beginning and at the end of each stage, patients will be submitted to serum TMAO and intestinal microbiota evaluation. For the intestinal microbiota evaluation, the new generation sequencing will be used in the highly preserved portion of the 16S subunit of the rRNA gene. The determination of TMAO in plasma will be by liquid chromatography coupled to mass spectrometry. Expected results: It is expected to determine if RW acts on the intestinal flora to the point of influencing plasma TMAO concentration.

Enrollment

42 patients

Sex

Male

Ages

45 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Men, 45-70 years
  2. Established atherosclerotic diseases defined as:

A. Previous history of CAD: angina or acute myocardial infarction (AMI), myocardial revascularization or angioplasty, angiographic evidence of stenosis ≥50% in at least one of the major coronary arteries B. Cerebrovascular disease: transient ischemic stroke or cerebrovascular accident C. Peripheral arterial disease: clinical evidence of extracoronary atherosclerosis

Exclusion criteria

  1. Acute events in the last 30 days (AMI, troponin elevation, coronary angioplasty or coronary artery bypass grafting)
  2. Heart Failure (NYHA functional class ≥ II)
  3. Renal Failure (clearance creatinine <30 mL / min by the Cockcroft-Gault formula)
  4. Hepatic Failure
  5. Gastro-intestinal cancer
  6. Intestinal inflammatory diseases
  7. Obstructive biliary diseases
  8. Prior gastrointestinal surgeries: cholecystectomy or colectomy
  9. Use of antibiotics within the last 2 months or during protocol
  10. Alcoholism or alcohol intolerance
  11. Diabetes mellitus or use of antidiabetics drugs

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

42 participants in 2 patient groups

Red Wine group (RW)
Experimental group
Description:
After a two weeks washout period,in the intervening period with red wine, patients will receive 250 mL / day of red wine per Day, 5 days a week, for 3 weeks.
Treatment:
Dietary Supplement: Red Wine consumption
Abstemious
Active Comparator group
Description:
After a two weeks washout period,in the Abstemious period, patients should not consume any kind of alcohol beverages, for 3 weeks
Treatment:
Other: Period without alcohol consumption

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems